28 results on '"AUGELLO, Giuseppa"'
Search Results
2. The potential of the nutraceutical berberine in the treatment of hepatocellular carcinoma and other liver diseases such as NAFLD and NASH
- Author
-
Cervello, Melchiorre, Augello, Giuseppa, Cocco, Lucio, Ratti, Stefano, Follo, Matilde Y., Martelli, Alberto M., Cusimano, Antonella, Montalto, Giuseppe, and McCubrey, James A.
- Published
- 2024
- Full Text
- View/download PDF
3. Extracellular Vesicle-Related Non-Coding RNAs in Hepatocellular Carcinoma: An Overview.
- Author
-
Augello, Giuseppa, Cusimano, Alessandra, Cervello, Melchiorre, and Cusimano, Antonella
- Subjects
- *
RNA physiology , *EXTRACELLULAR vesicles , *DRUG resistance in cancer cells , *MICRORNA , *CELL physiology , *TUMOR markers , *METASTASIS , *PATHOLOGIC neovascularization , *HEPATOCELLULAR carcinoma , *DISEASE progression - Abstract
Simple Summary: Hepatocellular carcinoma is a highly malignant tumor with increasing prevalence worldwide. Extracellular vesicles exert their biological functions via the delivery of different biomolecules, including non-coding RNAs. In this review, the diverse roles of the non-coding RNA cargo of hepatocellular carcinoma-derived extracellular vesicles will be discussed. Their function in tumor progression, immune escape, and drug resistance, as well as their potentialvalue as biomarkers of disease, will be summarized. Hepatocellular carcinoma (HCC) is the most common primary liver cancer. It is a major public health problem worldwide, and it is often diagnosed at advanced stages, when no effective treatment options are available. Extracellular vesicles (EVs) are nanosized double-layer lipid vesicles containing various biomolecule cargoes, such as lipids, proteins, and nucleic acids. EVs are released from nearly all types of cells and have been shown to play an important role in cell-to-cell communication. In recent years, many studies have investigated the role of EVs in cancer, including HCC. Emerging studies have shown that EVs play primary roles in the development and progression of cancer, modulating tumor growth and metastasis formation. Moreover, it has been observed that non-coding RNAs (ncRNAs) carried by tumor cell-derived EVs promote tumorigenesis, regulating the tumor microenvironment (TME) and playing critical roles in the progression, angiogenesis, metastasis, immune escape, and drug resistance of HCC. EV-related ncRNAs can provide information regarding disease status, thus encompassing a role as biomarkers. In this review, we discuss the main roles of ncRNAs present in HCC-derived EVs, including micro(mi) RNAs, long non-coding (lnc) RNAs, and circular (circ) RNAs, and their potential clinical value as biomarkers and therapeutic targets. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
4. Genetic Biomarkers of Sorafenib Response in Patients with Hepatocellular Carcinoma.
- Author
-
Giannitrapani, Lydia, Di Gaudio, Francesca, Cervello, Melchiorre, Scionti, Francesca, Ciliberto, Domenico, Staropoli, Nicoletta, Agapito, Giuseppe, Cannataro, Mario, Tassone, Pierfrancesco, Tagliaferri, Pierosandro, Seidita, Aurelio, Soresi, Maurizio, Affronti, Marco, Bertino, Gaetano, Russello, Maurizio, Ciriminna, Rosaria, Lino, Claudia, Spinnato, Francesca, Verderame, Francesco, and Augello, Giuseppa
- Subjects
GENETIC risk score ,HEPATOCELLULAR carcinoma ,SORAFENIB ,DRUG absorption ,BIOMARKERS - Abstract
The identification of biomarkers for predicting inter-individual sorafenib response variability could allow hepatocellular carcinoma (HCC) patient stratification. SNPs in angiogenesis- and drug absorption, distribution, metabolism, and excretion (ADME)-related genes were evaluated to identify new potential predictive biomarkers of sorafenib response in HCC patients. Five known SNPs in angiogenesis-related genes, including VEGF-A, VEGF-C, HIF-1a, ANGPT2, and NOS3, were investigated in 34 HCC patients (9 sorafenib responders and 25 non-responders). A subgroup of 23 patients was genotyped for SNPs in ADME genes. A machine learning classifier method was used to discover classification rules for our dataset. We found that only the VEGF-A (rs2010963) C allele and CC genotype were significantly associated with sorafenib response. ADME-related gene analysis identified 10 polymorphic variants in ADH1A (rs6811453), ADH6 (rs10008281), SULT1A2/CCDC101 (rs11401), CYP26A1 (rs7905939), DPYD (rs2297595 and rs1801265), FMO2 (rs2020863), and SLC22A14 (rs149738, rs171248, and rs183574) significantly associated with sorafenib response. We have identified a genetic signature of predictive response that could permit non-responder/responder patient stratification. Angiogenesis- and ADME-related genes correlation was confirmed by cumulative genetic risk score and network and pathway enrichment analysis. Our findings provide a proof of concept that needs further validation in follow-up studies for HCC patient stratification for sorafenib prescription. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
5. Lipid nanocarriers containing sorafenib inhibit colonies formation in human hepatocarcinoma cells
- Author
-
Bondì, Maria Luisa, Botto, Chiara, Amore, Erika, Emma, Maria Rita, Augello, Giuseppa, Craparo, Emanuela Fabiola, and Cervello, Melchiorre
- Published
- 2015
- Full Text
- View/download PDF
6. Preclinical evaluation of antitumor activity of the proteasome inhibitor MLN2238 (ixazomib) in hepatocellular carcinoma cells
- Author
-
Augello, Giuseppa, Modica, Martina, Azzolina, Antonina, Puleio, Roberto, Cassata, Giovanni, Emma, Maria Rita, Di Sano, Caterina, Cusimano, Antonella, Montalto, Giuseppe, and Cervello, Melchiorre
- Published
- 2018
- Full Text
- View/download PDF
7. New Insights into the Behavior of NHC-Gold Complexes in Cancer Cells.
- Author
-
Augello, Giuseppa, Azzolina, Antonina, Rossi, Filomena, Prencipe, Filippo, Mangiatordi, Giuseppe Felice, Saviano, Michele, Ronga, Luisa, Cervello, Melchiorre, and Tesauro, Diego
- Subjects
- *
CANCER cells , *TRIPLE-negative breast cancer , *CELL survival , *REACTIVE oxygen species , *DNA repair , *DNA damage , *GOLD clusters , *APOPTOSIS - Abstract
Among the non-platinum antitumor agents, gold complexes have received increased attention owing to their strong antiproliferative effects, which generally occur through non-cisplatin-like mechanisms of action. Several studies have revealed that many cytotoxic gold compounds, such as N-heterocyclic carbene (NHC)-gold(I) complexes, are potent thioredoxin reductase (TrxR) inhibitors. Many other pathways have been supposed to be altered by gold coordination to protein targets. Within this frame, we have selected two gold(I) complexes based on aromatic ligands to be tested on cancer cells. Differently from bis [1,3-diethyl-4,5-bis(4-methoxyphenyl)imidazol-2-ylidene]gold(I) bromide (Au4BC), bis [1-methyl-3-acridineimidazolin-2-ylidene]gold(I) tetrafluoroborate (Au3BC) inhibited TrxR1 activity in vitro. Treatment of Huh7 hepatocellular carcinoma (HCC) cells, and MDA-MB-231 triple-negative breast cancer (TNBC) cells, with Au4BC inhibited cell viability, increased reactive oxygen species (ROS) levels, caused DNA damage, and induced autophagy and apoptosis. Notably, we found that, although Au3BC inhibited TrxR1 activity, no effect on the cell viabilities of HCC and BC cells was observed. At the molecular level, Au3BC induced a protective response mechanism in Huh7 and MDA-MB-231 cells, by inducing up-regulation of RAD51 and p62 protein expression, two proteins involved in DNA damage repair and autophagy, respectively. RAD51 gene knock-down in HCC cells increased cell sensitivity to Au3BC by significant reduction of cell viability, induction of DNA damage, and induction of apoptosis and autophagy. All together, these results suggest that the tested NHC-Gold complexes, Au3BC and Au4BC, showed different mechanisms of action, either dependent or independent of TrxR1 inhibition. As a result, Au3BC and Au4BC were found to be promising candidates as anticancer drugs for the treatment of HCC and BC. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
8. Outcome predictors in SARS-CoV-2 disease (COVID-19): The prominent role of IL-6 levels and an IL-6 gene polymorphism in a western Sicilian population.
- Author
-
Giannitrapani, Lydia, Augello, Giuseppa, Mirarchi, Luigi, Amodeo, Simona, Veronese, Nicola, Sasso, Bruna Lo, Giglio, Rosaria Vincenza, Licata, Anna, Barbagallo, Mario, Ciaccio, Marcello, Cervello, Melchiorre, and Soresi, Maurizio
- Abstract
• Serum IL-6 levels predict COVID-19 disease severity and unfavorable outcomes. • An IL-6 gene variant is a predictor of COVID-19 disease severity and unfavorable outcomes. • Age and ischemic heart disease are important negative prognostic factors for COVID-19 disease. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
9. Effects of TP53 Mutations and miRs on Immune Responses in the Tumor Microenvironment Important in Pancreatic Cancer Progression.
- Author
-
McCubrey, James A., Yang, Li V., Abrams, Stephen L., Steelman, Linda S., Follo, Matilde Y., Cocco, Lucio, Ratti, Stefano, Martelli, Alberto M., Augello, Giuseppa, and Cervello, Melchiorre
- Subjects
PANCREATIC cancer ,TUMOR microenvironment ,CANCER invasiveness ,P53 protein ,IMMUNE response - Abstract
Approximately 90% of pancreatic cancers are pancreatic ductal adenocarcinomas (PDAC). PDAC is the fourth leading cause of cancer death world-wide. Therapies for PDAC are largely ineffective due to the dense desmoplastic tumor microenvironment which prevents chemotherapeutic drugs and small molecule inhibitors from exerting effective anti-cancer effects. In this review, we will discuss the roles of TP53 and miRs on the PDAC tumor microenvironment and how loss of the normal functions of TP53 promote tumor progression. The TP53 gene is mutated in approximately 50% of pancreatic cancers. Often, these TP53 mutations are point mutations which confer additional functions for the TP53 proteins. These are called gain of function (GOF) mutations (mut). Another class of TP53 mutations are deletions which result in loss of the TP53 protein; these are referred to TP53-null mutations. We have organized this review into various components/properties of the PDAC microenvironment and how they may be altered in the presence of mutant TP53 and loss of certain miR expression. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
10. miR-126-3p and miR-21-5p as Hallmarks of Bio-Positive Ageing; Correlation Analysis and Machine Learning Prediction in Young to Ultra-Centenarian Sicilian Population.
- Author
-
Accardi, Giulia, Bono, Filippa, Cammarata, Giuseppe, Aiello, Anna, Herrero, Maria Trinidad, Alessandro, Riccardo, Augello, Giuseppa, Carru, Ciriaco, Colomba, Paolo, Costa, Maria Assunta, De Vivo, Immaculata, Ligotti, Mattia Emanuela, Lo Curto, Alessia, Passantino, Rosa, Taverna, Simona, Zizzo, Carmela, Duro, Giovanni, Caruso, Calogero, and Candore, Giuseppina
- Subjects
SUCCESSFUL aging ,MACHINE learning ,STATISTICAL correlation ,MICRORNA ,AGING ,ENDOTHELIAL cells - Abstract
Human ageing can be characterized by a profile of circulating microRNAs (miRNAs), which are potentially predictors of biological age. They can be used as a biomarker of risk for age-related inflammatory outcomes, and senescent endothelial cells (ECs) have emerged as a possible source of circulating miRNAs. In this paper, a panel of four circulating miRNAs including miR-146a-5p, miR-126-3p, miR-21-5p, and miR-181a-5p, involved in several pathways related to inflammation, and ECs senescence that seem to be characteristic of the healthy ageing phenotype. The circulating levels of these miRNAs were determined in 78 healthy subjects aged between 22 to 111 years. Contextually, extracellular miR-146a-5p, miR-126-3p, miR-21-5p, and miR-181a-5p levels were measured in human ECs in vitro model, undergoing senescence. We found that the levels of the four miRNAs, using ex vivo and in vitro models, progressively increase with age, apart from ultra-centenarians that showed levels comparable to those measured in young individuals. Our results contribute to the development of knowledge regarding the identification of miRNAs as biomarkers of successful and unsuccessful ageing. Indeed, they might have diagnostic/prognostic relevance for age-related diseases. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
11. The NUPR1/p73 axis contributes to sorafenib resistance in hepatocellular carcinoma.
- Author
-
Augello, Giuseppa, Emma, Maria Rita, Azzolina, Antonina, Puleio, Roberto, Condorelli, Lucia, Cusimano, Antonella, Giannitrapani, Lydia, McCubrey, James A., Iovanna, Juan Lucio, and Cervello, Melchiorre
- Subjects
- *
SORAFENIB , *HEPATOCELLULAR carcinoma , *NUCLEAR proteins , *DRUG approval , *SMALL molecules , *CELL survival , *PROTEINS , *RESEARCH , *LIVER tumors , *AUTOPHAGY , *ANIMAL experimentation , *RESEARCH methodology , *APOPTOSIS , *EVALUATION research , *COMPARATIVE studies , *EPITHELIAL cells , *DRUG resistance in cancer cells , *MICE - Abstract
The multikinase inhibitor sorafenib was the first drug approved by the FDA for treating patients with advanced hepatocellular carcinoma (HCC). However, sorafenib resistance remains a major challenge for improving the effectiveness of HCC treatment. Previously, we identified several genes modulated after sorafenib treatment of human HCC cells, including the stress-inducible nuclear protein 1 (NUPR1) gene. Multiple studies have shown that NUPR1 regulates autophagy, apoptosis, and chemoresistance. Here, we demonstrate that treatment of HCC cells with sorafenib resulted in the activation of autophagic flux. NUPR1 knock-down (KD) in HCC cells was associated with increased p62 expression, suggesting an impairment of autophagic flux, and with a significant increase of cell sensitivity to sorafenib. In NUPR1 KD cells, reduced levels of NUPR1 were associated with the increased expression of p73 as well as its downstream transcription targets PUMA, NOXA, and p21. Simultaneous silencing of p73 and NUPR1 in HCC cells resulted in increased resistance to sorafenib, as compared to the single KD of either gene. Conversely, pharmacological activation of p73, via the novel p73 small molecule activator NSC59984, determined synergistic anti-tumor effects in sorafenib-treated HCC cells. The combination of NSC59984 and sorafenib, when compared to either treatment alone, synergistically suppressed tumor growth of HCC cells in vivo. Our data suggest that the activation of the p73 pathway achieved by NUPR1 KD potentiates sorafenib-induced anti-tumor effects in HCC cells. Moreover, combined pharmacological therapy with the p73 activator NSC59984 and sorafenib could represent a novel approach for HCC treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
12. The Prevalence of NAFLD and Fibrosis in Bariatric Surgery Patients and the Reliability of Noninvasive Diagnostic Methods.
- Author
-
Soresi, Maurizio, Cabibi, Daniela, Giglio, Rosaria V., Martorana, Stefania, Guercio, Giuseppina, Porcasi, Rossana, Terranova, Antonino, Lazzaro, Luigi A., Emma, Maria R., Augello, Giuseppa, Cervello, Melchiorre, Pantuso, Gianni, Montalto, Giuseppe, and Giannitrapani, Lydia
- Subjects
BIOPSY ,DIAGNOSIS ,DIGESTIVE organs ,FATTY liver ,BARIATRIC surgery ,OVERWEIGHT persons ,RELIABILITY (Personality trait) ,FIBROSIS ,DISEASE prevalence ,DESCRIPTIVE statistics - Abstract
Background. Bariatric surgery patients have a higher prevalence of nonalcoholic fatty liver (NAFL) than the general population; however, its assessment and the accurate staging of fibrosis are often complicated because noninvasive tests are not very accurate in patients with morbid obesity, and liver biopsy cannot be performed as a routine exam. The aim of this study was to evaluate (A) the histological prevalence of NAFL, nonalcoholic steatohepatitis (NASH), and fibrosis in patients undergoing bariatric surgery; (B) the reliability of ultrasound (US) in diagnosing NAFL; and (C) the reliability of various fibrosis scoring systems for defining fibrosis. Methods. US and intraoperative liver biopsy results were reviewed in 57 bariatric surgery patients. NAFL, NASH, and fibrosis were diagnosed according to the Kleiner scoring system. US diagnosis of liver steatosis was based on the bright liver. Fibrosis scores used were (i) the BMI, AST/ALT Ratio, Diabetes (BARD) scoring system; (ii) the nonalcoholic fatty liver disease (NAFLD) fibrosis score; and (iii) the fibrosis-4 (FIB-4) index. Results. The prevalence of NAFL was 81%, NASH 61.4%, and fibrosis 94% (F3 5.7%, cirrhosis 2.8%). The sensitivity of US was 95%, specificity 50%, and likelihood ratio (LR+, LR-) 1.91 and 0.1. The reliability of fibrosis scores for F ≥ 2 were as follows: BARD score: sensitivity 46%, specificity 54%, and area under the receiver-operating characteristics (AUROC) curve 0.5; NAFLD score: sensitivity 30%, specificity 89%, and AUROC 0.5; and FIB-4: sensitivity 68%, specificity 67%, and AUROC 0.7. Conclusions. In bariatric surgery patients, the prevalence of NAFL was 81%, NASH 61.4%, and fibrosis 94%. US is able to rule out the presence of NAFL, while the commonly used scores may be inaccurate in defining fibrosis in patients with morbid obesity. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
13. Targeting HSP90 with the small molecule inhibitor AUY922 (luminespib) as a treatment strategy against hepatocellular carcinoma.
- Author
-
Augello, Giuseppa, Emma, Maria Rita, Cusimano, Antonella, Azzolina, Antonina, Mongiovì, Sarah, Puleio, Roberto, Cassata, Giovanni, Gulino, Alessandro, Belmonte, Beatrice, Gramignoli, Roberto, Strom, Stephen C., McCubrey, James A., Montalto, Giuseppe, and Cervello, Melchiorre
- Abstract
Hepatocellular carcinoma (HCC) is a highly malignant tumor that responds very poorly to existing therapies, most probably due to its extraordinary inter‐ and intra‐tumor molecular heterogeneity. The modest therapeutic response to molecular targeted agents underlines the need for new therapeutic approaches for HCC. In our study, we took advantage of well‐characterized human HCC cell lines, differing in transcriptomic subtypes, DNA mutation and amplification alterations, reflecting the heterogeneity of primary HCCs, to provide a preclinical evaluation of the specific heat shock protein 90 (HSP90) inhibitor AUY922 (luminespib). Indeed, HSP90 is highly expressed in different tumor types, but its role in hepatocarcinogenesis remains unclear. Here, we analyzed HSP90 expression in primary human HCC tissues and evaluated the antitumor effects of AUY922 in vitro as well as in vivo. HSP90 expression was significantly higher in HCC tissues than in cirrhotic peritumoral liver tissues. AUY922 treatment reduced the cell proliferation and viability of HCC cells in a dose‐dependent manner, but did not do so for normal human primary hepatocytes. AUY922 treatment led to the upregulation of HSP70 and the simultaneous depletion of HSP90 client proteins. In addition, in a cell type‐dependent manner, treatment induced either both caspase‐dependent β‐catenin cleavage and the upregulation of p53, or Mcl‐1 expression, or NUPR1 expression, which contributed to the increased efficacy of, or resistance to, treatment. Finally, in vivo AUY922 inhibited tumor growth in a xenograft model. In conclusion, HSP90 is a promising therapeutic target in HCC, and AUY922 could be a drug candidate for its treatment. What's new? Hepatocellular carcinoma (HCC) exhibits vast molecular heterogeneity, suggesting that therapies aimed against targets that interact with multiple signaling pathways could be key to improving HCC outcome. Here, heat shock protein 90 (HSP90), a modulator of numerous signaling components, was found to be highly expressed in HCC. AUY922, an HSP90 inhibitor, blocked HCC cell growth in vitro and, in HepG2 liver carcinoma cells, induced apoptosis via caspase activation and β‐catenin fragmentation. These effects were not observed in Huh7 or SNU475 HCC cell lines. AUY922 also reduced tumor growth in vivo, marking HSP90 as a promising therapeutic target in HCC. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
14. Association Between <italic>MICA</italic> Gene Variants and the Risk of Hepatitis C Virus-Induced Hepatocellular Cancer in a Sicilian Population Sample.
- Author
-
Augello, Giuseppa, Balasus, Daniele, Fusilli, Caterina, Mazza, Tommaso, Emma, Maria Rita, Giannitrapani, Lydia, Agliastro, Rosalia, Cervello, Melchiorre, and Montalto, Giuseppe
- Subjects
- *
HEPATITIS C virus , *LIVER cancer , *GENOTYPES , *CIRRHOSIS of the liver , *GENETIC polymorphisms - Abstract
There are currently no biomarkers that predict hepatocellular carcinoma (HCC) risk in patients with hepatitis C virus (HCV)-related cirrhosis. We investigated the relationships among major histocompatibility complex (
MHC ) class I chain-related gene A (MICA ) polymorphisms, plasma levels of soluble MICA (sMICA), and HCC risk in patients with HCV-related HCC. One hundred fifty-four HCV-related HCC patients, 93 HCV-related liver cirrhosis (LC) cases, and 244 healthy controls, all sampled from the native Sicilian population, were genotyped using the KASP™ single-nucleotide polymorphism genotyping method. TheMICA rs2596542 polymorphism showed that the G/G genotype was significantly more frequent in HCC than control subjects and LC patients (p < 0.005). ForMICA rs2596538 polymorphism, the C allele and C/C genotype were significantly more frequent in HCC than in controls and LC cases (p < 0.005), after controlling for potential confounders. These results demonstrate thatMICA rs2596542G/G, and particularly the rs2596538C/C polymorphism, are associated with the risk of developing HCV-related HCC in a Sicilian population sample. Importantly, using a machine learning classifier, we found that “age” and either rs2596542 or rs2596538 were important discriminating factors for patients with LC and HCC. Finally, sMICA levels significantly increased during HCV-related liver disease progression, while a significant relationship between both rs2596542 and rs2596538 genotypes and sMICA plasma levels was identified in patients with LC and HCC. In summary, theMICA rs2596538 and rs2596542 variants warrant further research for their clinical validity and utility in relationship to the risk of developing HCV-related HCC in independent populations. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
15. Cytokine profile of breast cell lines after different radiation doses.
- Author
-
Bravatà, Valentina, Minafra, Luigi, Forte, Giusi Irma, Cammarata, Francesco Paolo, Russo, Giorgio, Di Maggio, Federica Maria, Augello, Giuseppa, Lio, Domenico, and Gilardi, Maria Carla
- Subjects
BREAST cancer treatment ,IONIZING radiation ,CELL lines ,EPITHELIAL cells ,CYTOKINES - Abstract
Purpose: Ionizing radiation (IR) treatment activates inflammatory processes causing the release of a great amount of molecules able to affect the cell survival. The aim of this study was to analyze the cytokine signature of conditioned medium produced by non-tumorigenic mammary epithelial cell line MCF10A, as well as MCF7 and MDA-MB-231 breast cancer cell lines, after single high doses of IR in order to understand their role in high radiation response. Materials and methods: We performed a cytokine profile of irradiated conditioned media of MCF10A, MCF7 and MDA-MB-231 cell lines treated with 9 or 23 Gy, by Luminex and ELISA analyses. Results: Overall, our results show that both 9 Gy and 23 Gy of IR induce the release within the first 72 h of cytokines and growth factors potentially able to influence the tumor outcome, with a dose-independent and cell-line dependent signature. Moreover, our results show that the cell-senescence phenomenon does not correlate with the amount of ‘senescence-associated secretory phenotype’ (SASP) molecules released in media. Thus, additional mechanisms are probably involved in this process. Conclusions: These data open the possibility to evaluate cytokine profile as useful marker in modulating the personalized radiotherapy in breast cancer care. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
16. Pivotal roles of glycogen synthase-3 in hepatocellular carcinoma.
- Author
-
Cervello, Melchiorre, Augello, Giuseppa, Cusimano, Antonella, Emma, Maria Rita, Balasus, Daniele, Azzolina, Antonina, McCubrey, James A., and Montalto, Giuseppe
- Subjects
- *
LIVER cancer , *GLYCOGEN synthase kinase-3 , *SOMATOMEDIN , *CELL communication , *SERINE/THREONINE kinases , *PROGNOSIS - Abstract
Hepatocellular carcinoma (HCC) is one of the most common cancers in the world, and represents the second most frequently cancer and third most common cause of death from cancer worldwide. At advanced stage, HCC is a highly aggressive tumor with a poor prognosis and with very limited response to common therapies. Therefore, there is still the need for new effective and well-tolerated therapeutic strategies. Molecular-targeted therapies hold promise for HCC treatment. One promising molecular target is the multifunctional serine/threonine kinase glycogen synthase kinase 3 (GSK-3). The roles of GSK-3β in HCC remain controversial, several studies suggested a possible role of GSK-3β as a tumor suppressor gene in HCC, whereas, other studies indicate that GSK-3β is a potential therapeutic target for this neoplasia. In this review, we will focus on the different roles that GSK-3 plays in HCC and its interaction with signaling pathways implicated in the pathogenesis of HCC, such as Insulin-like Growth Factor (IGF), Notch, Wnt/β-catenin, Hedgehog (HH), and TGF-β pathways. In addition, the pivotal roles of GSK3 in epithelial-mesenchymal transition (EMT), invasion and metastasis will be also discussed. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
17. Oleocanthal exerts antitumor effects on human liver and colon cancer cells through ROS generation.
- Author
-
CUSIMANO, ANTONELLA, BALASUS, DANIELE, AZZOLINA, ANTONINA, AUGELLO, GIUSEPPA, EMMA, MARIA R., DI SANO, CATERINA, GRAMIGNOLI, ROBERTO, STROM, STEPHEN C., McCUBREY, JAMES A., MONTALTO, GIUSEPPE, and CERVELLO, MELCHIORRE
- Published
- 2017
- Full Text
- View/download PDF
18. Biocompatible Lipid Nanoparticles as Carriers To Improve Curcumin Efficacy in Ovarian Cancer Treatment.
- Author
-
Bondì, Maria Luisa, Emma, Maria Rita, Botto, Chiara, Augello, Giuseppa, Azzolina, Antonina, Di Gaudio, Francesca, Craparo, Emanuela Fabiola, Cavallaro, Gennara, Bachvarov, Dimcho, and Cervello, Melchiorre
- Published
- 2017
- Full Text
- View/download PDF
19. A PTEN inhibitor displays preclinical activity against hepatocarcinoma cells.
- Author
-
Augello, Giuseppa, Puleio, Roberto, Emma, Maria Rita, Cusimano, Antonella, Loria, Guido R., McCubrey, James A., Montalto, Giuseppe, and Cervello, Melchiorre
- Published
- 2016
- Full Text
- View/download PDF
20. In human retinoblastoma Y79 cells okadaic acid-parthenolide co-treatment induces synergistic apoptotic effects, with PTEN as a key player.
- Author
-
Di Fiore, Riccardo, Drago-Ferrante, Rosa, D'Anneo, Antonella, Augello, Giuseppa, Carlisi, Daniela, De Blasio, Anna, Giuliano, Michela, Tesoriere, Giovanni, and Vento, Renza
- Published
- 2013
- Full Text
- View/download PDF
21. Paclitaxel and beta-lapachone synergistically induce apoptosis in human retinoblastoma Y79 cells by downregulating the levels of phospho-Akt.
- Author
-
D'ANNEO, ANTONELLA, AUGELLO, GIUSEPPA, SANTULLI, ANDREA, GIULIANO, MICHELA, FIORE, RICCARDO DI, MESSINA, CONCETTA, TESORIERE, GIOVANNI, and VENTO, RENZA
- Subjects
- *
PACLITAXEL , *ANTINEOPLASTIC agents , *APOPTOSIS , *CELL death , *PROTEINS , *RETINOBLASTOMA , *THERAPEUTICS - Abstract
Paclitaxel (PTX) and beta-lapachone (LPC) are naturally occurring compounds that have shown a large spectrum of anticancer activity. In this article we show for the first time that PTX/LPC combination induces potent synergistic apoptotic effects in human retinoblastoma Y79 cells. Combination of suboptimal doses of PTX (0.3 nM) and LPC (1.5 µM) caused biochemical and morphological signs of apoptosis at 48 h of treatment. These effects were accompanied by potent lowering in inhibitor of apoptosis proteins and by activation of Bid and caspases 3 and 6 with lamin B and PARP breakdown. PTX/LPC combination acted by favoring p53 stabilization through a lowering in p-Akt levels and in ps166-MDM2, the phosphorylated-MDM2 form that enters the nucleus and induces p53 export and degradation. Treatment with wortmannin or transfection with a dominant negative form of Akt anticipated at 24 h the effects induced by PTX/LPC, suggesting a protective role against apoptosis played by Akt in Y79 cells. In line with these results, we demonstrated that Y79 cells contain constitutively active Akt, which forms a cytosolic complex with p53 and MDM2 driving p53 degradation. PTX/LPC treatment induced a weakness of Akt–MDM2–p53 complex and increased nuclear p53 levels. Our results suggest that phospho-Akt lowering is at the root of the apoptotic action exerted by PTX/LPC combination and provide strong validation for a treatment approach that targets survival signals represented by phospho-Akt and inhibitor of apoptosis proteins. J. Cell. Physiol. 222: 433–443, 2010. © 2009 Wiley-Liss, Inc. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
22. NUPR1 protects liver from lipotoxic injury by improving the endoplasmic reticulum stress response.
- Author
-
Borrello, Maria Teresa, Emma, Maria Rita, Listi, Angela, Rubis, Marion, Coslet, Sergiu, Augello, Giuseppa, Cusimano, Antonella, Cabibi, Daniela, Porcasi, Rossana, Giannitrapani, Lydia, Soresi, Maurizio, Pantuso, Gianni, Blyth, Karen, Montalto, Giuseppe, Pin, Christopher, Cervello, Melchiorre, and Iovanna, Juan
- Published
- 2021
- Full Text
- View/download PDF
23. Potential Uses of Olive Oil Secoiridoids for the Prevention and Treatment of Cancer: A Narrative Review of Preclinical Studies.
- Author
-
Emma, Maria Rita, Augello, Giuseppa, Di Stefano, Vita, Azzolina, Antonina, Giannitrapani, Lydia, Montalto, Giuseppe, Cervello, Melchiorre, Cusimano, Antonella, and González-Sarrías, Antonio
- Subjects
- *
OLIVE oil , *SECOIRIDOIDS , *CANCER prevention , *CANCER treatment , *MEDITERRANEAN diet - Abstract
The Mediterranean diet (MD) is a combination of foods mainly rich in antioxidants and anti-inflammatory nutrients that have been shown to have many health-enhancing effects. Extra-virgin olive oil (EVOO) is an important component of the MD. The importance of EVOO can be attributed to phenolic compounds, represented by phenolic alcohols, hydroxytyrosol, and tyrosol, and to secoiridoids, which include oleocanthal, oleacein, oleuropein, and ligstroside (along with the aglycone and glycosidic derivatives of the latter two). Each secoiridoid has been studied and characterized, and their effects on human health have been documented by several studies. Secoiridoids have antioxidant, anti-inflammatory, and anti-proliferative properties and, therefore, exhibit anti-cancer activity. This review summarizes the most recent findings regarding the pharmacological properties, molecular targets, and action mechanisms of secoiridoids, focusing attention on their preventive and anti-cancer activities. It provides a critical analysis of preclinical, in vitro and in vivo, studies of these natural bioactive compounds used as agents against various human cancers. The prospects for their possible use in human cancer prevention and treatment is also discussed. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
24. Can Be miR-126-3p a Biomarker of Premature Aging? An Ex Vivo and In Vitro Study in Fabry Disease.
- Author
-
Lo Curto, Alessia, Taverna, Simona, Costa, Maria Assunta, Passantino, Rosa, Augello, Giuseppa, Adamo, Giorgia, Aiello, Anna, Colomba, Paolo, Zizzo, Carmela, Zora, Marco, Accardi, Giulia, Candore, Giuseppina, Francofonte, Daniele, Di Chiara, Tiziana, Alessandro, Riccardo, Caruso, Calogero, Duro, Giovanni, Cammarata, Giuseppe, Coulouarn, Cédric, and Tikkanen, Ritva
- Subjects
PREMATURE aging (Medicine) ,ANGIOKERATOMA corporis diffusum ,EXTRACELLULAR vesicles ,LYSOSOMAL storage diseases ,AGING - Abstract
Fabry disease (FD) is a lysosomal storage disorder (LSD) characterized by lysosomal accumulation of glycosphingolipids in a wide variety of cytotypes, including endothelial cells (ECs). FD patients experience a significantly reduced life expectancy compared to the general population; therefore, the association with a premature aging process would be plausible. To assess this hypothesis, miR-126-3p, a senescence-associated microRNA (SA-miRNAs), was considered as an aging biomarker. The levels of miR-126-3p contained in small extracellular vesicles (sEVs), with about 130 nm of diameter, were measured in FD patients and healthy subjects divided into age classes, in vitro, in human umbilical vein endothelial cells (HUVECs) "young" and undergoing replicative senescence, through a quantitative polymerase chain reaction (qPCR) approach. We confirmed that, in vivo, circulating miR-126 levels physiologically increase with age. In vitro, miR-126 augments in HUVECs underwent replicative senescence. We observed that FD patients are characterized by higher miR-126-3p levels in sEVs, compared to age-matched healthy subjects. We also explored, in vitro, the effect on ECs of glycosphingolipids that are typically accumulated in FD patients. We observed that FD storage substances induced in HUVECs premature senescence and increased of miR-126-3p levels. This study reinforces the hypothesis that FD may aggravate the normal aging process. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
25. GSK-3 in liver diseases: Friend or foe?
- Author
-
Emma, Maria R., Augello, Giuseppa, Cusimano, Antonella, Azzolina, Antonina, Montalto, Giuseppe, McCubrey, James A., and Cervello, Melchiorre
- Subjects
- *
LIVER diseases , *FATTY liver , *GLYCOGEN synthase kinase , *CHRONIC hepatitis B , *HEPATITIS B virus , *PATHOLOGY - Abstract
Liver diseases, including hepatitis due to hepatitis B or C virus infection, non-alcoholic fatty liver disease, and hepatocellular carcinoma pose major challenges for overall health due to limited curative treatment options. Thus, there is an urgent need to develop new therapeutic strategies for the treatment of these diseases. A better understanding of the signaling pathways involved in the pathogenesis of liver diseases can help to improve the efficacy of emerging therapies, mainly based on pharmacological approaches, which influence one or more specific molecules involved in key signal transduction pathways. These emerging therapies are very promising for the prevention and treatment of liver diseases. One promising druggable molecular target is the multifunctional serine/threonine kinase, glycogen synthase kinase 3 (GSK-3). In this review, we discuss conditions in which GSK-3 is implicated in liver diseases. In addition, we explore newly emerging drugs that target GSK-3β, as well as their potential use in and impact on the management of liver diseases. • GSK-3 plays a complex and controversial role in different types of liver disease. • GSK-3 is a promising molecular target in liver diseases. • GSK-3 inhibitors may offer new possibilities for the treatment of liver diseases. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
26. The Role of GSK-3 in Cancer Immunotherapy: GSK-3 Inhibitors as a New Frontier in Cancer Treatment.
- Author
-
Augello, Giuseppa, Emma, Maria R., Cusimano, Antonella, Azzolina, Antonina, Montalto, Giuseppe, McCubrey, James A., and Cervello, Melchiorre
- Subjects
- *
GLYCOGEN synthase kinase , *CANCER treatment , *IMMUNOTHERAPY , *CANCER cells , *IMMUNE response , *PROGRAMMED cell death 1 receptors , *GLYCOGEN synthase kinase-3 - Abstract
The serine/threonine kinase glycogen synthase kinase-3 (GSK-3) was initially identified because of its key role in the regulation of glycogen synthesis. However, it is now well-established that GSK-3 performs critical functions in many cellular processes, such as apoptosis, tumor growth, cell invasion, and metastasis. Aberrant GSK-3 activity has been associated with many human diseases, including cancer, highlighting its potential therapeutic relevance as a target for anticancer therapy. Recently, newly emerging data have demonstrated the pivotal role of GSK-3 in the anticancer immune response. In the last few years, many GSK-3 inhibitors have been developed, and some are currently being tested in clinical trials. This review will discuss preclinical and initial clinical results with GSK-3β inhibitors, highlighting the potential importance of this target in cancer immunotherapy. As described in this review, GSK-3 inhibitors have been shown to have antitumor activity in a wide range of human cancer cells, and they may also contribute to promoting a more efficacious immune response against tumor target cells, thus showing a double therapeutic advantage. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
27. Identification of an LPS-Induced Chemo-Attractive Peptide from Ciona robusta.
- Author
-
Longo, Valeria, Longo, Alessandra, Martorana, Annamaria, Lauria, Antonino, Augello, Giuseppa, Azzolina, Antonina, Cervello, Melchiorre, and Colombo, Paolo
- Abstract
Background: Previously published work has demonstrated that the LPS injection of Ciona robusta leads to the overexpression of a truncated form of an immune-related mRNA (C8short) by means of Ciona robusta (CR) alternative polyadenylation (APA) (CR-APA). Methods: The 3D structure of the C8short-derived Ciona robusta chemo-attractive peptide (CrCP) was evaluated by homology modeling. The biological activity of the CrCP was studied in vitro using a primary human dermal cell line (HuDe). Real-Time PCR was used to investigate the expression levels of genes involved in cell motility. NF-κB signaling was studied by western blotting. Results: In silico modeling showed that CrCP displayed structural characteristics already reported for a short domain of the vertebrate CRK gene, suggesting its possible involvement in cell migration mechanisms. In vitro assays demonstrated that CrCP was capable of inducing the motility of HuDe cells in both wound healing and chemo-attractive experiments. qPCR demonstrated the capability of CrCP to modulate the expression of the matrix metalloproteinase-7 (MMP-7) and E-cadherin genes. Finally, western blot analysis demonstrated that treatment with CrCP induced activation of the NF-κB signaling pathway. Conclusion: Our results describe the characterization of the 3D structure and chemo-attractive activity of an LPS-induced CrCP peptide from Ciona robusta. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
28. Hepatic and circulating levels of PCSK9 in morbidly obese patients: Relation with severity of liver steatosis.
- Author
-
Emma, Maria R., Giannitrapani, Lydia, Cabibi, Daniela, Porcasi, Rossana, Pantuso, Gianni, Augello, Giuseppa, Giglio, Rosaria V., Re, Noemi Lo, Capitano, Adele R., Montalto, Giuseppe, Soresi, Maurizio, and Cervello, Melchiorre
- Subjects
- *
FATTY liver , *BLOOD cholesterol , *ASPARTATE aminotransferase - Abstract
Non-alcoholic fatty liver disease (NAFLD) is becoming the main cause of liver disease in Western countries, especially in morbidly obese patients (MOPs). The proprotein convertase subtilisin/kexin type 9 (PCSK9) has been recently studied because of its possible involvement in the pathogenesis of NAFLD, but its role, at least in MOPs, is still controversial. The aim of this study was to clarify the correlation between the circulating levels of the PCSK9 protein (cPCSK9) and its hepatic expression with the severity of liver damage in a population of MOPs with NAFLD undergoing bariatric surgery. PCSK9 mRNA was positively correlated with FASN, PPARγ and PPARα mRNAs, while no significant differences were found in PCSK9 mRNA expression in relation to the severity of liver steatosis, lobular inflammation and hepatocellular ballooning. In addition, hepatic PCSK9 protein expression levels were not related to histological parameters of lobular inflammation and hepatocyte ballooning, decreased significantly only in relation to the severity of hepatic steatosis, and were inversely correlated with ALT and AST serum levels. cPCSK9 levels in the whole population were associated with the severity of hepatic steatosis and were positively correlated to total cholesterol levels. In multivariate analysis, cPCSK9 levels were associated with age, total cholesterol and HbA1c. In conclusion, in MOPs our findings support a role for PCSK9 in liver fat accumulation, but not in liver damage progression, and confirm its role in the increase of blood cholesterol, which ultimately may contribute to increased cardiovascular risk in this population. • Hepatic PCSK9 protein expression levels decrease in relation to the severity of hepatic steatosis in MOPs. • cPCSK9 level is associated with the severity of hepatic steatosis in MOPs. • cPCSK9 level is positively correlated with total cholesterol level in MOPs. • cPCSK9 level in MOPs is associated with age, total cholesterol and HbA1c in multivariate analysis. • PCSK9 may contribute to increased cardiovascular risk in MOPs. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.